Leukemia subtype	Surveillance guidelines
Acute lymphoblastic leukemia	For patients treated with chemotherapy and radiation only:
		Annual CBC with differential up to 10 years after last treatment
		Annual measurement of serum electrolyte, creatinine, blood urea nitrogen, calcium, magnesium, and phosphorus levels; thyroid function test; urinalysis
		Echocardiography and electrocardiography every three to five years if findings on pretreatment evaluation were abnormal, or if signs or symptoms of heart failure are present
		Routine eye and dental examinations
		Chest radiography, pulmonary function testing, and audiometry as needed based on symptoms
		If treated before 1972, one-time hepatitis B surface antigen and hepatitis C antibody serum testing
		If treated before 1993, one-time hepatitis C antibody serum testing
	For patients treated with HSCT:
		CBC every one to two months for three years, then every three to six months for up to five years followed by annual testing
		One year post-HSCT: CD4 cell count, immunoglobulin levels, bone density testing, ophthalmic evaluation
		Annual measurement of serum electrolyte, creatinine, blood urea nitrogen, serum ferritin, urine microalbumin, vitamin D, glucose, A1C, testosterone (males) or follicle-stimulating hormone and luteinizing hormone (females) levels; liver function test; urinalysis; lipid profile; thyroid function test
		Annual dental examination
		If abnormal pre-HSCT pulmonary function test result, repeat as indicated with a change in clinical status
		Age- and sex-specific cancer screening
		Age-appropriate immunizations
	For patients treated with cranial or craniospinal irradiation:
		Low threshold for neuroimaging for neurologic symptoms
Acute myelogenous leukemia	For patients treated with chemotherapy and radiation only:
		CBC every one to two months for three years, then every three to six months for up to five years
		Echocardiography and electrocardiography every two years
		Radionuclide angiography or multiple-gated acquisition scan and Holter monitoring every five years
	For patients treated with HSCT:
		Same as for patients with acute lymphoblastic leukemia
Chronic lymphocytic leukemia	For patients being monitored without treatment:
		Routine history for symptoms that would prompt treatment (e.g., fatigue, weight loss, night sweats, fever)
		Routine physical examination, specifically evaluating for hepatosplenomegaly
		Periodic CBCs: If progressive anemia or thrombocytopenia, refer to hematologist
		Annual influenza vaccines
		Pneumococcal vaccination every five years
		Avoid live vaccines
		Age- and sex-specific cancer screening
	If treated:
		Referral to cardiologist for baseline evaluation
		Resting and stress echocardiography (frequency depending on baseline findings and other cardiac risk factors)
Chronic myelogenous leukemia	For patients treated with a tyrosine kinase inhibitor:
		CBC every three months: If neutropenia (absolute neutrophil count < 1,000 per μL [1.0 × 109 per L]) or thrombocytopenia (platelet count < 50 × 103 per μL [50 × 109 per L]), refer to hematologist
		Monitor for adverse effects including diarrhea, fluid retention, gastrointestinal upset, headache, muscle cramps, rash
	For patients treated with HSCT:
		Same as for patients with acute lymphoblastic leukemia